Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

VVT Med Announces First Patients Treated with VVT's ScleroSafe(TM) System in Italy

Operational Milestone Achieved Amidst Regulatory Overhang

By The Northwire Desk — AI Analysis May 26, 2026 · 08:00 VVTM · 0.17 VVT Med Inc.
Executive Summary
  • VVT Med announced the successful treatment of the first group of patients in Italy using its ScleroSafe™ System at Fondazione Villa Salus Hospital in Mestre, Venice.
  • The procedure was conducted by Dr. Luca Palombi and his team in collaboration with local distributor Uber Ros S.p.A.
  • This event marks a significant milestone in the company's European expansion following the distribution agreement signed on April 27, 2026.
  • The technology utilized is non-thermal, non-tumescent (NT-NT), enabling controlled sclerosant delivery with simultaneous blood aspiration without thermal energy or tumescent anesthesia.
  • CEO Erez Tetro expressed encouragement regarding growing interest in ScleroSafe among leading vein specialists in Europe and highlighted Italy as an important market for advanced venous care.
Material Impact
  • The news confirms the commercial execution of the distribution agreement signed on April 27, 2026, with Uber Ros S.p.A., which was previously rated Routine - Positive.
  • While clinically significant, this operational update does not resolve the ongoing Management Cease Trade Order (MCTO) issued by the BCSC on May 1, 2026, due to continuous disclosure defaults.
  • The MCTO remains in effect until audited financial statements for FY 2025 and interim filings for Q1 2026 are completed by June 29, 2026.
  • Trading restrictions on the CEO and CFO remain active, limiting insider trading activity and potential equity-based incentives during this period.
  • The positive clinical milestone is incremental to previous announcements regarding distribution partners (India in Nov 2025, Italy in April 2026) rather than a new market-moving event.
  • Given the regulatory overhang, the market impact is likely muted compared to the operational progress, as compliance risks remain unresolved.
VVTM · Price
Company Overview
  • Company: VVT Med Inc., focused on venous disease treatment solutions.
  • Flagship Product: ScleroSafe™ System, a catheter-directed sclerotherapy system for varicose veins.
  • Technology: Non-thermal, non-tumescent (NT-NT) solution allowing simultaneous sclerosant injection and blood aspiration.
  • Regulatory Status: FDA-cleared and CE-marked; received CDSCO approval in India in 2022.
  • Current Operations: Commercial rollout active in Europe (Italy, North Macedonia), India, and the U.S. (NorthWell Health).
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 12, 2026 · 17:00

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

Regulatory Jun 11, 2026 · 08:30

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

Financings May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 15, 2026 · 17:31

Governance Risks Persist Despite Commercial Traction

Regulatory May 01, 2026 · 19:44

VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

Regulatory